Gavin MacBeath - 20 Jan 2026 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Chief Executive Officer, Director
Signature
/s/ Zoran Zdraveski, Attorney-in-Fact
Issuer symbol
TCRX
Transactions as of
20 Jan 2026
Net transactions value
$0
Form type
4
Filing time
22 Jan 2026, 17:48:44 UTC
Previous filing
11 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MacBeath Gavin Chief Executive Officer, Director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM /s/ Zoran Zdraveski, Attorney-in-Fact 22 Jan 2026 0001738082

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Award $0 +1,165,000 $0.000000 1,165,000 20 Jan 2026 Voting Common Stock 1,165,000 $1.12 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney